The PolyNovo Ltd (ASX: PNV) share price has galloped out of its trading halt after the company announced its first sales of a new product and bumper revenue in March.
The PolyNovo share price hit a high of $1.82 shortly after trading resumed, up 11.65% on yesterday’s closing price.
The ASX healthcare share has since pulled back a little to $1.76, up 7.98%.
Let’s take a look at the details.
What’s the news pushing the PolyNovo share price higher?
The medical device company’s new product is an advanced wound care treatment called NovoSorb MTX.
It received approval from the United States Food and Drug Administration in September 2022.
PolyNovo announced it has sold the new treatment to two hospitals in the US. It said its first sales had “occurred faster than expected”.
PolyNovo is an Australian company that designs, develops, and manufactures dermal regeneration
solutions (NovoSorb BTM) using its patented NovoSorb biodegradable polymer technology.
It created NovoSorb MTX in response to feedback from clinicians, who told them some wounds don’t require the sealing membrane contained in the primary product, NovoSorb BTM.
NovoSorb MTX simplifies wound management and has wider applications for common wound-healing problems.
PolyNovo now expects to sell both products to clinicians in the future.
The company says NovoSorb MTX expands its addressable US market by an estimated AU$500 million.
NovoSorb MTX is indicated for use in partial and full-thickness wounds, pressure ulcers, venous ulcers, chronic and vascular ulcers, diabetic ulcers, and surgical and trauma wounds.
What did management say?
PolyNovo Chair David Williams said:
I often refer to PolyNovo as taking baby steps on an upward evolving sales trajectory responding to the untapped indications that surgeons have found for it and an evolving response to large untapped markets such as India, Japan, and China.
NovoSorb MTX gives us the opportunity to take a big step forward.
What else did PolyNovo announce today?
PolyNovo also announced revenue numbers for the month of March.
The company revealed unaudited revenue of $6.4 million in March. This is up 48.2% on the March 2022 revenue of $4.3 million.
During the month, the company achieved record sales of NovoSorb BTM worth $5.45 million.
Sales revenue (unaudited) for the nine months to 31 March 2023 now totals $41.1 million. This is a 49.8% boost compared to the prior corresponding period.
Since the start of the year, the company has gained 26 new hospital customers in the US, three in Canada, and three in Hong Kong.
In India, PolyNovo has trained its sales staff and deployed them to the regions, with the first sale already recorded.
Williams said:
Sales will be lumpy for some time, but the trajectory is clear, and we see exciting times ahead in multiple jurisdictions.
We believe the quick first sales we have had in India, Canada and Hong Kong are a good indicator of early adoption by surgeons.
PolyNovo share price snapshot
The PolyNovo share price is up 87% over the past year.
It has vastly outperformed the S&P/ASX All Ordinaries Index (ASX: XAO), which is down 1.3% over the same period.
The post PolyNovo share price soars 12% amid ‘exciting times ahead’ appeared first on The Motley Fool Australia.
FREE Beginners Investing Guide
Despite what some people may say – we believe investing in shares doesn’t have to be overwhelming or complicated…
For over a decade, we’ve been helping everyday Aussies get started on their journey.
And to help even more people cut through some of the confusion “experts’” seem to want to perpetuate – we’ve created a brand-new “how to” guide.
Yes, Claim my FREE copy!
*Returns as of April 3 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- Short sellers reveal 4 ways to spot dud ASX shares
- Here are the top 10 ASX 200 shares today
- Guess which ASX All Ords stock has just had its share price target slashed 30% by a top broker
- Are these ASX All Ords shares ready to buy at fundamentally fire sale prices?
- 3 ASX All Ords shares going gangbusters on Tuesday
Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended PolyNovo. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/jShrCwz
Stock Pick 